docetaxel anhydrous has been researched along with 1 alpha,24-dihydroxyvitamin d3 in 3 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (1 alpha,24-dihydroxyvitamin d3) | Trials (1 alpha,24-dihydroxyvitamin d3) | Recent Studies (post-2010) (1 alpha,24-dihydroxyvitamin d3) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 207 | 39 | 46 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kutner, A; Milczarek, M; Wietrzyk, J | 1 |
| Kutner, A; Maciejewska, M; Nasulewicz-Goldeman, A; Opolska, A; Switalska, M; Wietrzyk, J | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
3 other study(ies) available for docetaxel anhydrous and 1 alpha,24-dihydroxyvitamin d3
| Article | Year |
|---|---|
The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Calcitriol; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cisplatin; Dihydroxycholecalciferols; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Ergocalciferols; G1 Phase; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Resting Phase, Cell Cycle; Taxoids | 2007 |
The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Proliferation; Cisplatin; Dihydroxycholecalciferols; Docetaxel; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Idarubicin; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Pyrimidines; Taxoids | 2012 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |